Research Article: Durability of Effectiveness Between Users of Once-Weekly Semaglutide and Dipeptidyl Peptidase 4 Inhibitors (DPP–4i) in US Adults with Type 2 Diabetes
Abstract:
Long-term effectiveness and durability of glucose-lowering medications are important considerations in managing type 2 diabetes (T2D). This study aimed to compare durability of treatment efficacy of once-weekly (OW) semaglutide for T2D with that of the dipeptidyl peptidase 4 inhibitor (DPP–4i) class.
Introduction:
Type 2 diabetes (T2D) is a highly prevalent disease globally [1, 2]. Pharmacotherapy, in addition to proper diet and exercise, is the cornerstone of T2D treatment [3]. Noninsulin glucose-lowering agents currently used to treat T2D in the USA include biguanides, sulfonylureas, thiazolidinediones, ?-glucosidase inhibitors, meglitinides, dipeptidyl peptidase 4 inhibitors (DPP–4is), sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), GLP-1/glucose-dependent…
Read more